Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages.
Citations
744 citations
Cites background from "Phosphatidylserine-containing lipos..."
...Furthermore, recent studies have shown that liposome administration can alter macrophage phenotype in vivo in part by induction of ERK signaling after ingestion (53, 54)....
[...]
152 citations
Cites background from "Phosphatidylserine-containing lipos..."
...[77] suggests that this effect is due to increased IL-10 production by macrophages....
[...]
70 citations
64 citations
Cites background from "Phosphatidylserine-containing lipos..."
...In vivo, PSLs have been described to promote the resolution of inflammation by modulating macrophage function in a model for inflammatory bone loss and myocardial infarction [31,33]....
[...]
...In vitro, clearance of apoptotic cells and PSLs skews macrophages towards a tolerogenic phenotype [21,23,29-35]....
[...]
55 citations
References
234 citations
215 citations
212 citations
"Phosphatidylserine-containing lipos..." refers background in this paper
...Furthermore, PSLs can promote the resolution of inflammation in vivo.(2,15,16)...
[...]
209 citations
"Phosphatidylserine-containing lipos..." refers background in this paper
...However, PSLinduced increase in IL-10 by LPS-stimulated macrophages may depend on ERK activity, because ERK activity leads to IL-10 production.(47,48) Furthermore, PSLs inhibited the rapid activation of p38 MAPK and may result in the subsequent slow enhancement of ERK activity in LPS-stimulated...
[...]
157 citations
"Phosphatidylserine-containing lipos..." refers background in this paper
...loss, because it can induce other pro-inflammatory cytokines.(19,20) Recently, much attention has been paid to IL-17 as...
[...]